Adaptive Biotechnologies Corp
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
ADPT$30.26+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $70,495 | $47,920 |
| Short-term marketable securities (amortized cost of $156,246 and $174,186, respectively) | 156,485 | 174,374 |
| Accounts receivable, net | 50,365 | 41,731 |
| Inventory | 9,820 | 8,440 |
| Prepaid expenses and other current assets | 13,020 | 11,287 |
| Total current assets | 300,185 | 283,752 |
| Long-term assets | ||
| Property and equipment, net | 34,107 | 48,616 |
| Operating lease right-of-use assets | 40,616 | 45,767 |
| Long-term marketable securities (amortized cost of $13,220 and $33,682, respectively) | 13,234 | 33,660 |
| Restricted cash | 2,689 | 2,897 |
| Intangible assets, net | 1,726 | 3,425 |
| Goodwill | 118,972 | 118,972 |
| Other assets | 1,207 | 2,287 |
| Total assets | $512,736 | $539,376 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $6,467 | $7,265 |
| Accrued liabilities | 7,700 | 8,157 |
| Accrued compensation and benefits | 16,992 | 15,838 |
| Current portion of operating lease liabilities | 8,920 | 10,239 |
| Current portion of deferred revenue | 45,194 | 55,689 |
| Current portion of revenue interest liability, net | 4,642 | 865 |
| Total current liabilities | 89,915 | 98,053 |
| Long-term liabilities | ||
| Operating lease liabilities, less current portion | 70,228 | 79,148 |
| Deferred revenue, less current portion | 1,006 | 27,256 |
| Revenue interest liability, net, less current portion | 126,566 | 132,414 |
| Other long-term liabilities | 20 | 20 |
| Total liabilities | 287,735 | 336,891 |
| Commitments and contingencies (Note 12) | ||
| Shareholders’ equity | ||
| Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2025 and 2024; 153,779,418 and 147,773,744 shares issued and outstanding at December 31, 2025 and 2024, respectively | 15 | 14 |
| Additional paid-in capital | 1,581,848 | 1,506,353 |
| Accumulated other comprehensive gain | 253 | 166 |
| Accumulated deficit | (1,363,323) | (1,303,824) |
| Total Adaptive Biotechnologies Corporation shareholders’ equity | 218,793 | 202,709 |
| Noncontrolling interest | 6,208 | (224) |
| Total shareholders’ equity | 225,001 | 202,485 |
| Total liabilities and shareholders’ equity | $512,736 | $539,376 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.